Litigation Details for Azurity Pharmaceuticals, Inc. v. Bionpharma Inc. (D. Del. 2021)
✉ Email this page to a colleague
Azurity Pharmaceuticals, Inc. v. Bionpharma Inc. (D. Del. 2021)
| Docket | ⤷ Try a Trial | Date Filed | 2021-10-15 |
| Court | District Court, D. Delaware | Date Terminated | |
| Cause | 35:271 Patent Infringement | Assigned To | Leonard Philip Stark |
| Jury Demand | Plaintiff | Referred To | |
| Patents | 10,039,745; 10,154,987; 9,669,008; 9,808,442 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Azurity Pharmaceuticals, Inc. v. Bionpharma Inc.
The small molecule drug covered by the patents cited in this case is ⤷ Try a Trial .
Details for Azurity Pharmaceuticals, Inc. v. Bionpharma Inc. (D. Del. 2021)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2023-01-11 | 158 | Opinion - Memorandum Opinion | patent), 10,039,745 (the ’745 patent), 10,772,868 (the ’868 patent), and 10,154,987 (the ’987 patent). …applications issued as U.S. Patent Nos. 9,669,008 (the ’008 patent), 11,040,023 (the ’023 patent), 11,141,405 (the…the ’405 patent), 9,808,442 (the ’442 patent), 10,786,482 (the ’482 patent), 10,918,621 (the ’621 patent…The Third Wave patents differ from the First Wave patents in that the Third Wave patents claim formulations… The precise claim limitations differ from patent to patent, but the essence of each is a stable mix- | External link to document |
| 2023-03-08 | 184 | Brief - Opening Brief in Support | Decl. Ex. M) ’745 patent U.S. Patent No. 10,039,745 B2 (D.I. 9-5, 7/13/21 Shrestha…’023 patent U.S. Patent No. 11,040,023 B2 (D.I. 89-1, FAC Ex. A) ’405 patent …U.S. Patent No. 11,141,405 B2 (D.I. 1, Compl. Ex. A) ’442 patent U.S. Patent No. 9,808,442… Meaning ’008 patent U.S. Patent No. 9,669,008 B1 (D.I. * 9-3, 7/13… Ex. D) ’482 patent U.S. Patent No. 10,786,482 B2 (D.I. 9-12, 7/13 | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
